SEC Tracker
Get the app

Roivant Sciences ROIV

Roivant Sciences announces positive Phase 3 results

Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Routine
  1. Phase 3 CLARITY program for brepocitinib in NIU conducted by Priovant
  2. Results announced via Item 7.01 of Form 8-K

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Roivant Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Neurocrine Biosciences NBIX public float $9.5B, Jun 30, 2025
  2. Exelixis EXEL public float $9.4B, Jul 4, 2025
  3. BIO-TECHNE TECH public float $9.1B, Dec 31, 2025
  4. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.